secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-06-23T12:45:37+00:00
Accession:  0001193125-26-278582
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 1.03, 2.03, 2.05
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Therapeutics files for Chapter 11 bankruptcy; enters stalking horse asset sales to Lilly and Astellas
--------------------------------------------------------------------------------

- Filed voluntary Chapter 11 petition on June 23, 2026; stock suspended from Nasdaq on May 5, 2026, now trades on OTCQB.
- Entered stalking horse APA with Lilly for $50M to sell technology platforms including STAC-BBB, zinc finger, Modular Integrase, and prion program.
- Entered stalking horse APA with Astellas for $25M upfront plus up to $25M milestones for Fabry disease candidate isaralgagene civaparvovec.
- Obtained $30M DIP financing commitment from Northridge ATM, LLC to fund post-petition operations, subject to court approval.
- Board approved restructuring eliminating ~51 roles (~40% of workforce); expects $3-4M severance costs; retaining 77 employees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/0001193125-26-278582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526278582/d161847d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-278582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer